glp-1 and mash therapies: a new frontier in treatment Efficacy and safety of GLP-1
Description
Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action
Novo nordisk files for regulatory approval of once-weekly semaglutide with the fda for the treatment of type 2 diabetes
Overall, these physiological studies support the notion that GLP-1 and glucagon possess dose-dependent synergism, leading to enhanced suppression of food intake, plus increased resting energy expenditure
When you have a lot of fatty tissue and it's pretty much everywhere, it narrows vessels and airways
Bogunovic M, Dav SH, Tilstra JS, Chang DT, Harpaz N, Xiong H, et al
